

14 March 2025

Notice of Change of Share Registry

Next Science Limited (ASX:NXS) (“Next Science” or “the Company”) announces that the Company’s provider of securityholder registry services will be changing from MUFG Corporate Markets (AU) Limited to Automic Pty Ltd (“Automic”).

Effective from Monday, 17 March 2025, the address of the Company’s securities registers will be Automic’s Sydney office at Level 5, 126 Phillip Street, Sydney, New South Wales.

Automic’s contact details are as follows:

Address: Level 5, 126 Phillip Street
Sydney NSW 2000
Postal: GPO Box 5193
Sydney NSW 2001
Email: hello@automicgroup.com.au
Telephone: 1300 288 664 (within Australia)
+61 2 9698 5414 (outside Australia)

Shareholders can easily and efficiently manage their holdings via Automic’s secure online investor portal. Shareholders that are not already a user of Automic’s investor portal may visit <https://investor.automic.com.au> and sign up to register their details using a simple two-step process.

Shareholders with any queries in relation to their Next Science holding are advised to contact Automic at hello@automicgroup.com.au or on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia).

Approved and authorised for release by CEO & Managing Director

Media & Investor Enquiries

Françoise Dixon
Phone: +61 412 292 977
Email: fdixon@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company’s primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com